ClinicalTrials.gg
Enrolling by invitationNCT07298603Updated Oct 16, 2026

Nutrition Intervention for Women With Polycystic Ovary Syndrome

An interventional study of FertilOMed Diet and MedDiet in PCOS- Polycystic Ovary Syndrome, Nutrition Intervention and Nutrition Assessment, sponsored by Ondokuz Mayıs University. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.

Planned enrollment
21st of 29
36 · median 54
Started
2025
with 6 others
No phase
26 of 72
9 open now
Primary completion
2027-11
later than 14 of 14 live
Registered
56th of 72
by date

Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 21st largest by planned enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2025, is one of 26 with no phase, reaches primary completion later than 14 of the 14 other live ones, and was the 56th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Polycystic Ovary Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether different dietary models can improve clinical, metabolic, hormonal, anthropometric, and quality-of-life parameters in women with polycystic ovary syndrome (PCOS).

The main questions it aims to answer are:

  • Do the Mediterranean Diet and the FertilOMed Diet (Fertility-Optimized Mediterranean Diet) lead to significant improvements in these parameters compared to the control group?
  • Does the FertilOMed Diet lead to greater improvements compared to the standard Mediterranean Diet? Study Description: This randomized controlled intervention study will be conducted between November 2025 and March 2026 at the Samsun Training and Research Hospital, Department of Obstetrics and Gynecology, Women's Health Outpatient Clinics. Necessary institutional permissions have been obtained for conducting the study at these sites.

Participants: Women diagnosed with PCOS who meet the inclusion criteria and volunteer to participate will be included in the study.

Interventions:

Participants will be randomly assigned to one of the following groups:

  • Mediterranean Diet group
  • FertilOMed Diet group (Fertility-Optimized Mediterranean Diet)
  • Control group (standard dietary recommendations) Researchers will compare these groups to determine whether the dietary interventions improve clinical, biochemical, and symptomatic outcomes in women with PCOS.
Read the detailed description

This study will include volunteer female individuals who have applied to the Gynecology and Obstetrics outpatient clinic of the Gynecology and Obstetrics Department of Samsun Training and Research Hospital, diagnosed with PCOS by a physician, and selected according to inclusion and exclusion criteria. Women who meet the criteria will be informed about the study's objectives and methodology, and those who agree to participate will be asked to sign a consent form. Individuals will be assigned to control and intervention groups, matched by age and BMI. Care will be taken to ensure that the groups are matched by age and body mass index (BMI). At the beginning of the study, a questionnaire containing sociodemographic information, general health information, dietary habits, physical activity status, sleep habits, morningness-eveningness scale, PCOS-50 Quality of Life scale, Beck depression scale, SF-36 scale, and food consumption record will be administered to the individuals via face-to-face interviews by the researcher. Initial anthropometric measurements of the female volunteers will be taken by the researcher using appropriate techniques. Additionally, biochemical findings will be obtained from hospital records at the beginning and end of the study. Volunteers, matched by age and BMI, were included in the control and intervention groups and will be followed for 12 weeks. Individuals in the control group will receive only medical treatment throughout the study period. They will be free to make food choices without energy restrictions (ad libitum). No dietary intervention will be implemented. Individuals in the intervention groups will receive ad libitum nutrition education and brochures about the diet's content, in addition to their medical treatment. Individuals in both intervention groups will not be restricted in their daily dietary energy intake.

During the 12-week follow-up period, individuals will be closely monitored through mobile applications and routine follow-up visits.

03

Conditions studied

  • PCOS- Polycystic Ovary Syndrome
  • Nutrition Intervention
  • Nutrition Assessment

Keywords

  • polycystic ovary syndrome
  • FertilOMed Diet
  • Mediterranean Diet
  • dietary intervention
  • reproductive health
  • Quality of life
  • oxidative stress
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being diagnosed with PCOS according to the Rotterdam Criteria, between the ages of 20 and 45,
  • Having a (BMI) of 18.50-35.00 kg/m2,
  • Not having used antibiotics and/or probiotics in the last month,
  • Signing a voluntary consent form.

Exclusion criteria

Exclusion Criteria:

  • Being younger than 20 years old or older than 45 years old with PCOS diagnosis,
  • Having a of ≤18.50 kg/m2 and ≥35.00 kg/m2,
  • Being pregnant or breastfeeding,
  • Using alcohol,
  • Having used antibiotics and/or probiotics in the last month,
  • Having had bariatric surgery,
  • Having type 1 diabetes, type 2 diabetes, Cushing's syndrome, hypothyroidism, androgen tumors, active cancer, or a gastrointestinal system or malabsorption disease,
  • Having used hormonal or insulin sensitivity-enhancing medications within 3 months before the study start,
  • Having used antioxidant supplements such as vitamin C within 1 month before the study start,
  • Having a Mediterranean Diet Adherence Score (MEDAS) of ≥10,
  • Those who did not give their consent after reading the form.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Mediterranean Diet group

    Participants follow Mediterranean Diet

    Other: MedDiet

  • Experimental
    FertilOMed Diet

    Participants follow Fertility-Optimized Mediterranean Diet

    Other: FertilOMed Diet

  • No intervention
    Control

    Participants receive standard dietary recommendations

Interventions

  • OtherFertilOMed Diet

    FertilOMed Diet (Experimental): Participants will follow the FertilOMed Diet, which is based on the standard Mediterranean Diet guidelines, with required consumption of specific foods and adherence to recommended food group portions. Dietary adherence will be monitored through food diaries and follow-up consultations.

  • OtherMedDiet

    Mediterranean Diet (Active Comparator): Participants will follow a standard Mediterranean Diet for the duration of the study. Dietary adherence will be monitored through food diaries and follow-up consultations.

06

What researchers measure

Primary outcomes

  1. Changes in Hormonal Profile

    The primary outcome measure of this study is to evaluate holistic changes in the reproductive-metabolic profile of individuals with PCOS following the dietary intervention. This composite outcome includes coordinated changes in hormonal balance (e.g., FSH, LH, Estradiol, Progesterone, 17-Hydroxyprogesterone, DHEAS, T4, TSH, Prolactin, SHBG, AMH, Total Testosterone, and FAI). All parameters will be measured at baseline and after the 12-week dietary intervention, and changes will be analyzed to determine the overall impact of the applied dietary model. These parameters will be obtained by scanning the participants' routine results from their file information.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  2. Changes in Metabolic Profile

    The primary outcome measure of this study is to evaluate holistic changes in the reproductive-metabolic profile of individuals with PCOS following the dietary intervention. This composite outcome includes coordinated changes in metabolic profile (e.g., , AST, ALT, Hemogram, D Vitamini, B12 Vitamini, SHBG, HbA1c, AMH, Total Testosteron, Glukoz, İnsülin, HOMA IR, HDL, LDL, Trigliserit, Total Kolesterol). All parameters will be measured at baseline and after the 12-week dietary intervention, and changes will be analyzed to determine the overall impact of the applied dietary model. These parameters will be obtained by scanning the participants' routine results from their file information.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  3. Changes in Oxidative Stress

    The primary outcome measure of this study is to evaluate holistic changes in the reproductive-metabolic profile of individuals with PCOS following the dietary intervention. This composite outcome includes coordinated changes in hormonal balance (e.g.,TAC, Vit C, SOD, Catalase, Glutathione Peroxidase (GPx) and Malondialdehyde (MDA)). All parameters will be measured at baseline and after the 12-week dietary intervention, and changes will be analyzed to determine the overall impact of the applied dietary model. These parameters will be determined by performing validated commercial ELISA kits in accordance with the manufacturer's instructions and evaluating with a microplate reader.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

Secondary outcomes

  1. Changes in Body Mass Index (BMI)

    Body mass index (BMI) will be calculated using weight (kg) and height (m²). Although weight and height will be measured, only BMI (kg/m²) will be reported as the outcome variable. Changes in BMI from baseline to the end of the 12-week dietary intervention will be evaluated to assess the impact of the intervention on anthropometric status.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  2. Change in Waist Circumference

    Anthropometric parameter used to assess central adiposity.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  3. Change in Hip Circumference

    Anthropometric parameter used to evaluate lower-body fat distribution.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  4. Change in Waist-to-Hip Ratio

    Derived anthropometric index reflecting fat distribution.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  5. Change in Neck Circumference

    Anthropometric indicator associated with upper-body fat distribution.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  6. Change in Body Fat Percentage

    Body fat percentage will be measured using the TANITA BC-545N bioelectrical impedance device under standardized conditions (8-hour fasting, light clothing, removal of metal/electronic items). Changes from baseline to Week 12 will be assessed.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  7. Change in Lean Mass

    Lean mass will be measured using the TANITA BC-545N device under standardized measurement conditions. Changes from baseline to Week 12 will be evaluated.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  8. Change in Muscle Mass

    Muscle mass will be assessed via TANITA BC-545N using standardized fasting and measurement procedures. Change from baseline to Week 12 will be recorded.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  9. Change in Total Body Water

    Total body water will be assessed via TANITA BC-545N. Device output will be reported as percentage (%) or liters (L), depending on the measurement format. Changes from baseline to Week 12 will be evaluated.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  10. Change in Depression Symptoms (Beck Depression Inventory)

    Depressive symptoms will be evaluated using the Beck Depression Inventory (BDI).

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  11. Change in PCOS-Specific Quality of Life (PCOSQ-50)

    The PCOSQ-50 questionnaire assesses PCOS-specific quality of life across multiple domains.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

  12. Change in Health-Related Quality of Life (SF-36)

    The SF-36 evaluates general health-related quality of life.

    Time frame: Participants follow the dietrary intervention and are assessed at baseline and at the end of the 12-week intervention.

07

Study locations

1 site
  • Ondokuz Mayıs University Kurupelit Campus
    Samsun, Atakum, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 23 months is above that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Mar 2026 → Nov 2027 and completion May 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 23, 2025
StartActual
Dec 3, 2025
Primary completionEst.
Nov 30, 2027was Mar 2026
CompletionEst.
Dec 30, 2028was May 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 30, 2026→Nov 30, 2027
Oct 16, 2026
Study completion
May 30, 2026→Dec 30, 2028
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Mar 30, 2026→Nov 30, 2027
    Study completion May 30, 2026→Dec 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07298603
Responsible party
Menşure Nur ÇELİK (Principal Investigator, Ondokuz Mayıs University) — Principal investigator
First posted
Dec 23, 2025
Start date
Dec 3, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion